MARKET WIREYahoo Finance UK • 18h ago
HUTCHMED (China) Limited (0013.HK) stock price, news, quote and historyYahoo Finance UK report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.
Why HCM Stock dropped -3.24% Today — RQD Quant Desk Flash
$13.15 -3.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $13.05
HUTCHMED (China) Limited (HCM) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $2.29B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on HCM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is HCM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, HUTCHMED (China) Limited (NASDAQ: HCM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $13.15 (-3.24% 1D, market cap $2.29B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, HCM ranks #622 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does HCM compare to RCUS and PBH in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HCM carries a Roarable E (34/100 RQD), trailing P/E of 5.2x, gross margin of —, and ROIC of -2.5%. By comparison, RCUS (Arcus Biosciences Inc.) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $2.32B) and PBH (Prestige Consumer Healthcare Inc.) posts a C grade (62/100 RQD, P/E 12.1x, ROIC 13.8%, cap $2.32B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while HRMY leads on capital efficiency (63.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for HCM?
▼
Per HCM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001648257), HUTCHMED (China) Limited generated $548.5M in revenue (-13.0% YoY), $456.9M in net income, and -$78.8M in free cash flow against $1.75B in total assets and $68.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $13.05 (-0.77%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-10.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HCM)Realized 20D OHLCV Swing Band: ±5.7%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY HCM SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (35% of score)
Altman Z-Score 3.63 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+7/20 pts (21% of score)
SEC Form 4 / 13F Thermometer: 35% Net Buy • Dilution Drag (+1.36% YoY Shares)
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$13.50+9.2% Next Q
42
Q2 (-2Q)Grade E$14.74-6.4% Next Q
39
Q3 (-1Q)Grade E$13.80-4.7% Next Q
37
CurrentGrade E$13.15-8.7% Hist 90D α
34
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a HCM Turnaround Squeeze
While HCM currently carries a cautious 34/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.69) and Max Pain ($13.81) forces dealer call-delta covering toward $17.15.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $HCM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HCM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why HCM Stock dropped -3.24% Today — RQD Quant Desk Flash
HUTCHMED (China) Limited (HCM) dropped -3.24% to $13.15, trading at 52% of its 52-week range ($9.77 – $16.33). Stretched risk/reward at 5x P/E (-3% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 52% of its 52-week range ($9.77 – $16.33) with RSI-14 at 42.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±5.7% around $13.15 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 38.7% gross margin and $0 annual free cash flow.
Live HCM Headlines & Catalysts
MARKET WIREYahoo Finance • 21h ago
HUTCHMED (AIM:HCM) Stock Looks Expensive Relative To Current EarningsYahoo Finance report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A GSK subsidiary closes its HUTCHMED (HCM) drug deal; up to $1.185B in milestones may follow.Stock Titan report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
HUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy?MarketBeat report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
What HUTCHMED (China) (AIM:HCM)'s GSK Drug Licensing Deal Means For ShareholdersSimply Wall St report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 1d ago
HUTCHMED (China) stock trades below USD 14.87 consensus targetad-hoc-news.de report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Lung cancer trial investigator Yi-Long Wu will lead HUTCHMED (HCM)'s November 5 webcast.Stock Titan report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.
CATALYSTwww.siam.in • 1d ago
HUTCHMED (HCM) Notches +0.79% Gain — Bulls Tighten Grip 2026-10-18 - Small Cap Breakoutswww.siam.in report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 1d ago
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan— Follows US FDA new drug application submission in September 2026, marking important global regulatory progress — — Filings supported by positive SAFFRON global Phase III data demonstrating statistically significant and
MARKET WIREYahoo • 3d ago
3 British Healthcare Stocks To Own In October 2026Tech stocks are under pressure after disappointing AI related earnings, which has pushed some investors to look for sectors with different drivers. That is where leading British healthcare stocks come in. These companies
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HCM)
- ✓Walkthrough of HCM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
HCM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -0.53%🛡️ HOLDING TREND SUPPORT
2026-11-03O $13.59H $13.59L $13.15C $13.15VOL 33.5K
RES: $16.66SUP: $12.73SMA50: $13.69SMA200: $13.20
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
HCM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
-13.3%/yr Implied 5Y Growth
vs. -13.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on HCM today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for HCM. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HCM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HCM)
Health Care Rank #622 of 1016
⚔️ RCUS vs HCM Full Matrix →
1. Head-to-Head Health Care Peer Comparison (HCM vs. RCUS, PBH, BHVN, HRMY)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, HUTCHMED (China) Limited (HCM) ranks #622 by composite RQD confidence (34/100, grade E) and #233 by equity capitalization ($2.29B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while HRMY leads on capital efficiency and profitability with 63.0% ROIC and 77.2% gross margin. HRMY currently holds the highest overall quantitative score in the immediate peer group at 86/100 (A) compared with HCM at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HCM
ACTIVE
HUTCHMED (China) Limited | E | 34/100 | 5.2x | — | -2.5% | -3.24% | $2.29B | Benchmark Subject |
| RCUS Arcus Biosciences Inc. | E | 19/100 | — | — | -35.0% | -2.26% | $2.32B | /rcus-vs-hcm → |
| PBH Prestige Consumer Healthcare Inc. | C | 62/100 | 12.1x | 54.7% | 13.8% | +0.64% | $2.32B | /pbh-vs-hcm → |
| BHVN Biohaven Ltd. | D | 44/100 | — | — | -35.0% | -6.49% | $2.33B | /bhvn-vs-hcm → |
| HRMY Harmony Biosciences Holdings Inc. | A | 86/100 | 14.2x | 77.2% | 63.0% | +0.44% | $2.26B | /hrmy-vs-hcm → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001648257In its most recent audited fiscal period (FY2025, filed 2025-12-31), HUTCHMED (China) Limited (HCM) reported GAAP revenue of $548.5M (-13.0% vs. FY2024 revenue of $630.2M , and -34.5% cumulative change since FY2023) , GAAP net income of $456.9M, operating cash flow of -$64.7M, and free cash flow of -$78.8M (-352.0% YoY). On the balance sheet, HCM closed FY2025 with $1.75B in total assets against $68.2M in total debt (Altman Z-Score: 3.63, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $548.5M | $456.9M | -$64.7M | -$78.8M | $1.75B | $68.2M |
| FY2024 (FY) | 2024-12-31 | $630.2M | $37.7M | $497.0K | -$17.4M | $1.27B | $59.4M |
| FY2023 (FY) | 2023-12-31 | $838.0M | $100.8M | $219.3M | $219.3M | — | — |
3. HCM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs HCM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, HUTCHMED (China) Limited (NASDAQ: HCM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $13.15 (-3.24% 1D, market cap $2.29B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, HCM ranks #622 in composite RQD confidence.
How does HCM compare to RCUS and PBH in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HCM carries a Roarable E (34/100 RQD), trailing P/E of 5.2x, gross margin of —, and ROIC of -2.5%. By comparison, RCUS (Arcus Biosciences Inc.) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $2.32B) and PBH (Prestige Consumer Healthcare Inc.) posts a C grade (62/100 RQD, P/E 12.1x, ROIC 13.8%, cap $2.32B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while HRMY leads on capital efficiency (63.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for HCM?
Per HCM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001648257), HUTCHMED (China) Limited generated $548.5M in revenue (-13.0% YoY), $456.9M in net income, and -$78.8M in free cash flow against $1.75B in total assets and $68.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is HCM trading relative to its 50-day, 200-day, and 52-week technical levels?
HCM last traded at $13.15 (-3.24% on volume of 33,496 shares), positioning the stock -3.94% below its 50-day simple moving average ($13.69) and -0.38% below its 200-day simple moving average ($13.20). Across its 52-week range of $9.77 to $16.33, HCM sits at the 51.5% percentile with a 14-day RSI of 42.4 (NEUTRAL RANGE) and an implied next-earnings move of ±5.7% ($12.40 to $13.90).
HCM Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is HCM stock moving today?
Why HCM Stock dropped -3.24% Today — RQD Quant Desk Flash. Stretched risk/reward at 5x P/E (-3% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 34/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
HCM — HUTCHMED (China) Limited: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:25:57Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, HCM scores 42 out of 100, grade D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: the Fundamental Cash Engine scores 4/20 (ROIC -2.5%; FCF yield -3.32%), which is the weakest pillar and reflects value destruction and negative free cash flow. Whale 13F Flow scores 9/20 and Insider Conviction scores 7/20, indicating weak smart-money and insider support in the source data. Macro Regime Fit scores 10/20 with a beta of 1.0 and sector sensitivity noted. Forensic Balance Sheet scores 12/20, drawing on an Altman Z of 3.63, a Piotroski F of 4/9, and a debt-to-equity of 0.06; this is the strongest pillar, indicating the balance sheet is less distressed than the cash flow and flow signals. For a prospective investor, the implication is that the low headline P/E of 5.2 (TTM) is not a clean value signal: per the Roarable RQD rating, the cash engine and ownership-flow pillars are weak, so upside depends on the company converting its reported earnings into durable cash, which the source data does not yet show. The balance-sheet pillar offers some downside cushion, but the rating as a whole points to caution rather than conviction.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $548.5M | $-39.2M | $456.9M | N/A | $-78.8M | $71.3M | $68.2M |
| FY 2024 | $630.2M | $-43.7M | $37.7M | N/A | $-17.4M | $154.0M | $59.4M |
| FY 2023 | $838.0M | $18.4M | $100.8M | N/A | $219.3M | N/A | N/A |
Per the SEC financials, revenue declined from $838.0M (FY 2023) to $630.2M (FY 2024) and $548.5M (FY 2025), while operating income turned negative in both FY 2024 and FY 2025. FY 2025 net income of $456.9M sits far above operating income of $-39.2M, a gap the source data does not explain. Per the Roarable RQD rating and market data, ROIC is -2.5%, the operating margin is -7.1%, and the gross margin is listed as 0%. The Altman Z-Score is 3.63 and the Piotroski F-Score is 4/9, per the Roarable RQD rating, while the debt-to-equity ratio is 0.06; FY 2025 cash of $71.3M against debt of $68.2M is consistent with a modest, but declining, cash position.
Recent Catalysts & News Wire Analysis
- Per the news feed, a Yahoo Finance UK report published in the last hour covers HCM market action and institutional positioning (light: YELLOW, "MARKET WIRE").
- Per the news feed, a Yahoo Finance report describes the stock as looking expensive relative to current earnings.
- Per the news feed, a Stock Titan report states that a GSK subsidiary closed its HUTCHMED drug deal, with up to $1.185B in milestones possibly to follow; this is the most material catalyst in the source data.
- Per the news feed, a MarketBeat report describes shares gapping up.
- Per the news feed, a Simply Wall St report analyzes the GSK drug licensing deal's implications for shareholders.
- Per the news feed, an ad-hoc-news.de report states the stock trades below a USD 14.87 consensus target.
- Risk watch items: the expensive-vs-earnings framing, and the gap between reported net income and operating loss. Proprietary signals: Not available in source data (the Butterfly graph lists none).
Open Questions
- What drives the gap between FY 2025 net income of $456.9M and operating income of $-39.2M, and is the net income recurring?
- What is the timing and probability of the GSK milestone payments up to $1.185B, and how do they change the FCF trajectory?
- What are HCM's product lines, revenue mix, and customer concentration?
- Why is gross margin listed as 0%, and what does it imply about cost of revenue?
- Who holds the stock institutionally, and what are the recent insider and 13F flows?
HCM Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for HUTCHMED (China) Limited (HCM) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance UK • 18h ago
HUTCHMED (China) Limited (0013.HK) stock price, news, quote and history Yahoo Finance UK report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 21h ago
HUTCHMED (AIM:HCM) Stock Looks Expensive Relative To Current Earnings Yahoo Finance report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A GSK subsidiary closes its HUTCHMED (HCM) drug deal; up to $1.185B in milestones may follow. Stock Titan report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
HUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy? MarketBeat report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
What HUTCHMED (China) (AIM:HCM)'s GSK Drug Licensing Deal Means For Shareholders Simply Wall St report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 1d ago
HUTCHMED (China) stock trades below USD 14.87 consensus target ad-hoc-news.de report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Lung cancer trial investigator Yi-Long Wu will lead HUTCHMED (HCM)'s November 5 webcast. Stock Titan report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST www.siam.in • 1d ago
HUTCHMED (HCM) Notches +0.79% Gain — Bulls Tighten Grip 2026-10-18 - Small Cap Breakouts www.siam.in report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
HCM Bull vs. Bear Conversation Board — What's Your Call at $13.15?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HCM 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $11.96 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is HCM (D- • RQD 42/100) a Buy at $13.59?
Welcome to the HCM (HUTCHMED (China) Limited) Roar Pit. Current RQD Composite is 42/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $11.42 (-16.0%)
Spot @ $13.59 Pump the brakes on HCM — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on HCM, but look at what you are paying: 5.2x trailing P/E with tightening sector spreads. Unless HUTCHMED (China) Limited expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH
🎯 Target: $16.85 (+24.0%)
Spot @ $13.59 HCM cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on HCM, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $13.59 (52-wk range $9.77 - $16.33), any beat on forward guidance forces shorts and underweight funds to chase.